Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Conditions: Relapsed/Refractory Rhabdomyosarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcoma; Ewing Sarcoma Intervention: Drug: Eribulin mesylate Sponsor: Eisai Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bone Cancers | Ewing's Sarcoma | Pediatrics | Research | Rhabdomyosarcoma | Sarcomas | Soft Tissue Sarcoma | Study